

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
01 November 2018 (01.11.2018)

WIPO | PCT

(10) International Publication Number  
**WO 2018/200918 A8**

## (51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)

## (21) International Application Number:

PCT/US2018/029728

## (22) International Filing Date:

27 April 2018 (27.04.2018)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/492,056 28 April 2017 (28.04.2017) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **BRYCH, Stephen, Robert**; 2488 Gillingham Circle, Thousand Oaks, CA 91362 (US). **WONG, Lyanne, M.**; 28861 Silversmith Drive, Valencia, CA 91354 (US). **FALLON, Jaymille**; 28915 Thousand Oaks Blvd, #187,

Agoura Hills, CA 91301 (US). **GOSS, Monica, Michelle**; 3050 Lodgewood Street, Newbury Park, CA 91320 (US). **GU, Jian, Hua**; 1525 Silver Shadow Drive, Thousand Oaks, CA 91320 (US). **GHATTYVENKATAKRISHNA, Pavan, K.**; 285 Third Street N121, Cambridge, MA 02142 (US).

(74) Agent: **HONG, Julie, J.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME




FIGURE 1

(57) Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

**(48) Date of publication of this corrected version:**

14 November 2019 (14.11.2019)

**(15) Information about Correction:**

see Notice of 14 November 2019 (14.11.2019)

**Previous Correction:**

see Notice of 17 October 2019 (17.10.2019)